1. Zemaira. [Prescribing Information] Kankakee, IL: CSL Behring LLC; April 2013.
2. Aralast NP [Prescribing Information] Westlake Village, CA: Baxter Healthcare Corporation; March 2014.
3. Glassia [Prescribing Information] Westlake Village, CA; Baxter Healthcare Corporation; March 2014.
4. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma 1-antitrypsin, Respitin. Chest. 2002;122:66-74.
5. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with 1-antitrypsin: patterns of use and adverse events. Chest. 2003;123(5):1425-1434.
6. ATS/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Respir Care Med. 2003; 168:818-900.
7. DRUGDEXR Database [Internet database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically. Accessed June 30, 2015.
8. Prolastin-C. [Prescribing Information] Research Triangle Park, NC: Grifols Therapeutics Inc.; November 2013.
9. Micromedex Healthcare Series [Internet Database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically. Accessed January 19, 2016
10. Aralast. American Hospital Formulary Service Drug Information. Available at: http://www.medicinescomplete.com/mc/ahfs/current/. Accessed January 19,2016.
11. Glassia. American Hospital Formulary Service Drug Information. Available at: http://www.medicinescomplete.com/mc/ahfs/current/. Accessed January 19.2016.
12. Prolastin-C. American Hospital Formulary Service Drug Information. Available at: http://www.medicinescomplete.com/mc/ahfs/current/. Accessed January 19,2016.
13. Zemaira. American Hospital Formulary Service Drug Information. Available at: http://www.medicinescomplete.com/mc/ahfs/current/. Accessed January 19,2016.